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Abstract: Botulinum toxin type A is a high molecular weight protein complex containing active 
neurotoxin and complexing proteins, the latter of which, it is believed, protect the neurotoxin 
when in the gastrointestinal tract, and may facilitate its absorption. Comparisons of conventional 
botulinum toxin type A drugs that include complexing proteins with the complexing protein-
free formulation of Xeomin® strongly suggest that complexing proteins do not affect diffusion 
of the active neurotoxin. Studies of Xeomin have also shown that complexing proteins do not 
enhance product stability in storage. However, complexing proteins may stimulate antibody 
development against botulinum toxin type A. Numerous observational studies have been 
published showing that some patients receiving conventional botulinum toxin may develop 
neutralizing antibodies, leading to antibody-induced therapy failure. Studies have shown that 
Xeomin is not associated with the development of neutralizing antibodies in animal models or 
in patients. In conclusion, complexing proteins do not contribute to the stability of botulinum 
toxin type A drugs and do not contribute to their therapeutic effects, but may be associated with 
a secondary nonresponse due to the development of neutralizing antibodies.
Keywords: botulinum toxin type A, neurotoxin, complexing proteins, neutralizing 
antibodies
Introduction
Commercial pharmaceutical preparations of botulinum toxin type A are an effective 
treatment for a large number of disorders resulting from increased muscle tone, such 
as cervical dystonia, hemifacial spasm, and blepharospasm.1 In addition, botulinum 
toxin type A is effective for the treatment of axillary and palmar hyperhidrosis2 and 
urologic disorders,3 and is associated with a high level of patient satisfaction when 
used in facial esthetic procedures.4
The active botulinum toxin (150 kDa) occurs naturally as part of a high molecular 
weight complex containing the neurotoxin moiety and a set of complexing proteins 
of clostridial origin.5 The proteins are also called neurotoxin-associated proteins.6 
  Conventional botulinum toxin type A drugs, including Botox® (Vistabel®, onabotuli-
numtoxin A; Allergan Inc, Irvine, CA) and Dysport® (Azzalure®, abobotulinumtoxinA; 
Ipsen Ltd, Berkshire, UK), contain these complexing proteins in addition to the 
  neurotoxin.7 More recently, a botulinum toxin type A-containing pharmaceutical 
preparation free from complexing proteins has been developed called Xeomin® (also 
known as incobotulinumtoxinA, NT 201, botulinum toxin type A [150 kDa], free from 
complexing proteins, Bocouture®; Merz Pharmaceuticals GmbH, Frankfurt, Germany). 
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Xeomin, regardless of their clinical indication. This new 
preparation is derived from a wild-type strain of Clostridium 
botulinum type A (ATCC 3502), and it contains only the 
active botulinum toxin type A with no complexing proteins7 
and has similar biologic activity to Botox.8 In comparative 
clinical trials, the efficacy and tolerability of Xeomin were 
noninferior to that of conventional botulinum toxin type A 
drugs.9,10 For example, the efficacy of Xeomin was compared 
with that of Botox in a 16-week randomized, double-blind, 
noninferiority trial in 463 patients with cervical dystonia.9 
Both treatments significantly improved the Toronto   Western 
Spasmodic Torticollis Rating Scale (TWSTRS) severity 
score compared with baseline, and noninferiority of Xeomin 
versus Botox was demonstrated.9 The TWSTRS represents 
the standard method to quantify cervical dystonia and is a 
sum of subscores for the rating of maximal excursion of the 
head, duration, and other symptoms. No clinically relevant 
differences between the two treatments were observed for any 
secondary efficacy variable or with regard to adverse events. 
Similarly, a randomized, double-blind study of Xeomin and 
Botox in 300 patients with blepharospasm found that both 
treatments significantly reduced the Jankovic Rating Scale 
(JRS) score from baseline, displaying noninferiority of 
Xeomin.10 The JRS is a standard rating scale which allows 
the quantification of typical symptoms of blepharospasm. 
Again, there were no significant differences between Xeomin 
and Botox on any efficacy or safety measure.
The purposes and effects of complexing proteins in 
botulinum toxin type A preparations are unclear, although 
suggested purposes include stabilization of the neurotoxin 
and enhancement of gastrointestinal uptake, and suggested 
effects include delay of botulinum toxin diffusion into adja-
cent tissues11 and formation of neutralizing antibodies against 
botulinum toxin type A, leading to subsequent treatment 
failure.6,12 This article reviews the literature and presents 
the latest thoughts on the role of complexing proteins in 
botulinum toxin type A preparations.
Structure and role  
of complexing proteins
In all naturally occurring serotypes of botulinum toxin 
(types A–G), the neurotoxin is noncovalently associated with 
complexing proteins and thus forms toxin complexes.13,14 
Complexing proteins are encoded in two gene clusters located 
close to each other on the C. botulinum chromosome.15,16 
The first cluster encodes botulinum toxin itself plus a 
nontoxic, nonhemagglutinin (NTNHA) protein, while the 
second encodes three hemagglutinin (HA) proteins (HA1, 
HA2, and HA3), with HA3 being cleaved in serotype A 
post-translationally into two smaller components (HA3a and 
3b). In botulinum toxin serotypes A–D and G, these com-
ponents form two different toxin complexes, ie, a medium 
toxin complex comprising botulinum toxin and NTNHA 
(300 kDa) and a large toxin complex that also includes the 
three HA molecules (500–600 kDa).5 In contrast, serotypes E 
and F produce only the medium toxin complex.13 Serotype A 
also forms a third complex with a higher molecular weight 
(900 kDa).5 The detailed molecular structure of botulinum 
toxin type D large toxin complex has been visualized and 
comprises a 14-subunit complex of neurotoxin, NTNHA, 
three HA3 molecules (a 70 kDa molecule, also known as 
HA-70), three HA2 (also known as HA-17), and six HA1 
(also known as HA-33, Figure 1).13 A denaturing capillary 
electrophoresis method was used to determine the subunits 
forming the very large/or higher molecular weight toxin 
complex of botulinum toxin type A, concluding that it con-
tains single copies of the 150 kDa neurotoxin and NTNHA 
subunits, as well as 5–6 HA-17, 4–5 HA-23, 3–4 HA-48, and 
8–9 HA-34 subunits, with a total mass of 880–1000 kDa.17
In nature, complexing proteins appear to have a number 
of functions. Based on differences in oral toxicity between 
NTNHA
BoNT
Zn2+
HA-70
HA-17
HA-33
Figure  1  Arrangement  of  components  in  botulinum  toxin  type  D  complex. 
Botulinum toxin is highlighted in red, the nontoxic, nonhemagglutinin protein in 
green, three HA-70 in yellow, six HA-33 in blue, and three HA-17 in cyan. The 
catalytic zinc ion in botulinum toxin is indicated by the orange circle and the arrow. 
Copyright© 2009 The American Society for Biochemistry and Molecular Biology. 
All rights reserved. Reproduced with permission from Hasegawa K, watanabe T, 
Suzuki T, et al. A novel subunit structure of Clostridium botulinum serotype D toxin 
complex with three extended arms. J Biol Chem. 2007;282:24777–24783.13 
Abbreviations:  BoNT,  botulinum  toxin;  NTNHA,  nontoxic,  nonhemagglutinin 
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toxin complexes of different sizes, it was initially suggested 
that the function of complexing proteins was the protection 
of the botulinum toxin moiety when in the gastrointestinal 
tract.18 This was subsequently confirmed in biochemical 
analyses (protease resistance) of different toxin species.19 
It has also been suggested that complexing proteins may 
stabilize the biologic activity of the neurotoxin in vivo and 
facilitate adherence to muscle tissue.20 In addition, com-
plexing proteins may have a role in limiting the diffusion of 
botulinum toxin out of the target tissues, due to the large size 
of the toxin complex.11,21,22 However, it was found that there 
was no difference in the diffusion of the free or complexed 
form after injection into the muscle.23 Orally ingested botu-
linum toxin must cross the epithelium of the gastrointestinal 
tract before it can affect muscle, and a role for complexing 
proteins in the uptake and transcytosis of botulinum toxin 
through the intestinal epithelium has been suggested.14,24 In 
the therapeutic setting, where botulinum toxin type A is not 
delivered orally, the roles of complexing proteins in protec-
tion from gastric pH extremes, resistance against stomach 
and intestinal proteases, and transport across the intestinal 
epithelium are not relevant to clinical efficacy. However, 
it should be noted that the lack of complexing proteins in 
Xeomin leads to a marked decrease in oral bioavailability 
and toxicity.25
While it is conceivable that complexing proteins are 
involved in botulinum toxin stability and in limiting 
botulinum toxin diffusion from the injection site (thereby 
minimizing adverse events), comparison of the complexing 
protein-free drug Xeomin with conventional botulinum 
toxin type A drugs suggests that this is not the case.26–28 To 
evaluate the role of complexing proteins, the stability of 
the 900 kDa botulinum toxin type A was analyzed using 
ion-exchange chromatography under various physiologic 
pH conditions.26,27 The 900 kDa toxin complex eluted as a 
single fraction at pH 6.0, but increasingly dissociated into 
several fractions as the pH value of the eluent increased.27 
At physiologic pH values, the active 150 kDa neurotoxin is 
efficiently released in less than one minute from the 900 kDa 
complex by a shift of the complex association-dissociation 
equilibrium to unbound 150 kDa neurotoxin.29 This is in 
contrast with the time to onset of therapeutic effect, which 
is measured in days. Therefore, it is unlikely that complexing 
proteins are essential for the stability of the 900 kDa toxin 
complex at physiologic pH or for limiting diffusion of the 
150 kDa botulinum toxin type A after injection of conven-
tional botulinum toxin type A drugs. The rapid dissociation 
of neurotoxin from the toxin complexes under physiologic 
conditions may also explain the similar adverse effect profile 
of Xeomin and conventional botulinum toxin type A drugs 
that contain complexing proteins.9,10,30 Although the injected 
product is different, the rapid dissociation would lead to the 
generation of the same active agent, ie, the 150 kDa botuli-
num toxin type A, eliciting the same diffusion characteristics 
and therapeutic effects. Indeed, earlier in vivo studies using 
different botulinum toxin type A drugs and a preparation of 
the free botulinum toxin type A (150 kDa) have shown that 
diffusion from the injection site does not differ between 
preparations.31 Similarly, studies using radiolabeled botuli-
num toxin type A have shown that there was no difference 
in the distribution of the free botulinum toxin type A or 
complexed botulinum toxin type A at or outside the injec-
tion site, even when using high doses.23 In the past, some 
confusion has occurred when comparing diffusion charac-
teristics between different botulinum toxin type A drugs in 
the clinical setting.22 For example, a review comparing the 
area of anhidrotic effect between Botox and Dysport con-
cluded that the diffusion of the two drugs differed as a result 
of numerous factors, including molecular size, dosing, and 
injection technique.21 However, the comparison failed to take 
into account the different potencies of the two drugs, which 
resulted in different anhidrotic areas.22,28 When botulinum 
toxin type A efficacy was evaluated by anhidrotic area across 
a range of Botox:Dysport dose ratios (1:2.5, 1:3, 1:4)32 and 
electromyography using a 1:3 Botox:Dysport dose ratio,33 
the different drugs were found to produce similar results. In 
contrast, one report demonstrated that Dysport had a greater 
area of diffusion in the forehead than Botox.34
Further evidence for a lack of effect of complexing 
proteins on botulinum toxin type A diffusion comes from 
clinical studies in which compound muscle action potential 
(CMAP) M-wave amplitudes were measured in patients 
receiving Xeomin or Botox. In a Phase I study, 14 healthy 
male   volunteers received repeated injections of Xeomin 
or Botox into the extensor digitorum brevis muscle of 
each foot.35 There were no statistically significant differ-
ences between the two treatments in terms of degree of 
paralysis, onset of action, or duration of paralysis (although 
time to onset of action was slightly earlier with Xeomin). 
This indicates their similar efficacy and diffusion profiles, 
neither showing any effect in adjacent muscles. In another 
Phase I study of similar design, no significant differences 
between Xeomin and Botox were observed in 32 healthy 
male volunteers.36 Furthermore, measurements in adjacent 
muscles found that CMAP M-wave amplitudes were greater 
than 80% of baseline at all post-injection visits (Figure 2),36 Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 2 Mean values of abductor hallucis muscle compound muscle action potential M-wave amplitudes are above threshold of effect after injection of NT 201 (Xeomin®) 
or BTXCo (Botox®) into the extensor digitorum brevis, indicating no relevant diffusion-induced effect in adjacent muscles.
Copyright© 2007. Adapted with permission from wolters Kluwer Health. wohlfarth K, Muller C, Sassin i, et al. Neurophysiological double-blind trial of a botulinum 
neurotoxin type a free of complexing proteins. Clin Neuropharmacol. 2007;30:86–94.36
Abbreviation: CMAP, compound muscle action potential.
suggesting no difference in diffusion-induced reduction of 
muscle activity. The diffusion of different botulinum toxin 
type A drugs was also investigated in a mouse study using 
a high-sensitivity test for muscle expression of neural cell 
adhesion molecule, which does not occur under physiologic 
conditions.37 Results of the neural cell adhesion molecule 
assay showed that injection of Botox, Dysport, and Xeomin 
(1:4:1 ratio) led to limited diffusion of botulinum toxin 
type A into adjacent muscles, with no significant differences 
between the formulations.
Another postulated effect of complexing proteins in 
a therapeutic context could be to enhance the stability of 
the botulinum toxin type A drug during storage. However, 
  studies of Xeomin do not corroborate this proposal.38 
The stability of Xeomin was evaluated in long-term storage 
studies and in short-term temperature-stress studies.38 The 
studies evaluated the neurotoxin content (via enzyme-linked 
immunosorbent assay), sucrose content (via enzymatic 
assay), and human serum albumin content (via high-pressure 
liquid chromatography) of vials containing Xeomin 
stored at 5°C or 25°C, as well as the biologic activity of 
the neurotoxin (mouse median lethal dose [LD50]). After 
48 months of storage at room temperature or in a refrigerator, 
no significant changes in neurotoxin, sucrose, or human 
serum albumin content or, most importantly, biologic 
activity, were observed in the Xeomin samples (Figure 3, 
data on file, Merz Pharmaceuticals GmbH).38 In contrast, 
all other licensed botulinum toxin type A drugs containing 
  complexing   proteins require refrigerated storage.39,40 
Furthermore, storage studies showed that Xeomin was stable 
for at least 18 months at 30°C and for at least six months 
at 40°C (data on file, Merz Pharmaceuticals GmbH).38 In 
short-term temperature-stress studies, all parameters tested 
remained within the release specifications when Xeomin 
was stored at 60°C for one month. At 80°C, the expected 
reduction of biologic activity occurred within five days, 
although proteolytic activity had not fallen to below one-third 
of the initial value after 10 days, with a decline over time 
considerably slower than for biologic   activity. Therefore, it 
appears that the binding and/or translocation domains of the 
neurotoxin are more sensitive to temperature changes than 
the light-chain protease (data on file, Merz Pharmaceuticals 
GmbH).38 Overall, these results demonstrate that complex-
ing proteins are not required to maintain the stability of 
botulinum toxin type A during storage.
Antibody formation  
and its consequences
While complexing proteins do not appear to have an effect 
on botulinum toxin type A stability or limit diffusion from 
the injection site, it is possible that they stimulate antibody 
production against the active neurotoxin. In a mouse study 
using formalin treated botulinum toxin type B (toxoid), the 
amount of neutralizing antibodies produced was greater 
when the botulinum toxin type B was complexed with a large 
toxin complex, compared with the toxoid supplemented with Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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hemagglutins, or when the neurotoxoid was administered 
alone.11 Further analysis showed that HA1 and HA3b were 
responsible for the adjuvant action, with HA2 producing no 
increase in antibody production. The mechanism of increased 
immune response to HA1 and HA3b appeared to be mediated 
by an increase in interleukin-6, leading to increased numbers 
of CD19-positive cells. In vitro enzyme-linked immunosor-
bent assay analysis of antibody binding to botulinum toxin 
type A large toxin complex showed that HA1 accounted for 
most of the immunogenic response.12 Although Attassi41 com-
mented that a formalin-treated neurotoxin (toxoid) was used 
and the experiment does not reflect the therapeutic situation 
in detail, Lee et al showed in the vaccination experiment that 
two HAs could enhance the antibody titer against the antigen 
and act as adjuvants.12
Antibodies against botulinum toxin type A can lead to 
treatment failure. In patients receiving therapeutic treat-
ment with conventional botulinum toxin type A drugs, 
case reports have been published describing patients with 
complete antibody-induced treatment failure using the 
original Botox formulation (20 U/ng) for hemifacial spasm 
(cumulative dose, 96 U)42 or cervical dystonia (cumulative 
dose, 2540 U).43 Similarly, four of 25 patients receiving 
Botox for urologic disorders developed high botulinum 
toxin type A antibody titers, which were associated with 
complete therapy failure in three cases (12% of patients 
overall), and a further four patients had borderline antibody 
titers (32% of patients overall).44 In a pooled analysis of data 
from patients with poststroke upper or lower limb spasticity 
receiving Botox, neutralizing antibodies were detected in 
one of 191 patients (0.5%); this patient (cumulative dose, 
960 U) showed no clinical response to treatment at any 
time.45 Of 880 patients treated with botulinum toxin type A 
for a variety of indications, five (0.6%) were positive for 
neutralizing antibodies, of whom four with cervical dysto-
nia (cumulative Botox exposure, 1200–3100 U) remained 
responsive, while the other patient had poststroke spasticity 
and developed antibodies after a single injection of 200 U 
Botox, with no response to botulinum toxin type A.46 In a 
recent study, four of 326 patients with cervical dystonia 
(1.2%) developed neutralizing antibodies (up to 15 cycles of 
Botox; median, nine cycles; mean cumulative dose, 1576 U), 
three of whom were clinically unresponsive.47 Another study 
found that five of 42 patients (11.9%) developed botulinum 
toxin type A antibodies following treatment with Botox 
(mean cumulative dose, 4610 ± 1936 U) and/or Dysport 
(14,033 ± 7566 U) for spasticity of various etiologies.48 Of 
these five patients, three had low titers (,0.3 mU/mL), one 
had an intermediate titer (0.6 mU/mL) and one had a high 
titer (.1.0 mU/mL) of antibodies.48 Two of the patients with 
0
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Figure 3 Xeomin® is stable at room temperature (25°C) over 48 months.38 
Reproduced with permission from Merz Pharmaceuticals GmbH, Frankfurt, Germany.
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low titers remained clinically responsive to therapy, while 
the other three patients were unresponsive to Botox and/or 
Dysport. Thus, the formation of neutralizing antibodies can 
result in partial or complete clinical unresponsiveness to 
botulinum toxin type A.49
The presence of complexing proteins in botulinum 
toxin type A drugs may lead to an increased risk of devel-
opment of neutralizing antibodies. Indeed, the original 
formulation of Botox was six times more likely to elicit 
the production of antibodies than the newer formulation, 
which contains fewer complexing proteins and reduced 
inactive neurotoxin.50 When data were analysed from 149 
patients with cervical dystonia who had received treatment 
with Botox, neutralizing antibodies were detected in four of 
42 patients (9.5%) who had received only the older formu-
lation (100 U/25 ng neurotoxin), compared with none of 
the 119 patients who had received only a newer formula-
tion (with a higher specific biologic activity of 100 U/5 ng 
botulinum toxin type A, P , 0.004).50 Complexing pro-
teins may also be associated with development of non-
neutralizing antibodies, with an estimated 40% of patients 
developing titers of antibodies against C. botulinum 
HA and NTNH molecules, although they do not impact 
upon the efficacy of the neurotoxin.51 Clearly, injection 
with complexed botulinum toxin represents a substantial 
increase in foreign protein load in addition to the 150 kDa 
botulinum toxin type A moiety.
Preliminary experiments with Xeomin suggest that 
the absence of complexing proteins is indeed associated 
with reduced immunogenicity. In a study in Cynomolgus 
  monkeys, repeated four-weekly injections with 4, 8, or 
16 U/kg Xeomin or control were not associated with the 
development of neutralizing antibodies in any animal, 
despite clear evidence of biologic activity of the neurotoxin, 
particularly in the highest dose group.52 However, this study 
lacked a positive control group and, therefore, confirmation 
of these data are required to show that complexing proteins 
result in antibody formation.
The immunogenicity of Xeomin in comparison with that 
of Botox and Dysport was evaluated in New Zealand white 
rabbits.53 After repeated intradermal injection, Xeomin did 
not induce the formation of neutralizing antibodies, unlike 
Botox and Dysport.53 In this study, both Xeomin and Botox 
were administered intradermally into female New Zealand 
white rabbits at 16 U/animal for eight administrations every 
2–8 weeks (data on file, Merz Pharmaceuticals GmbH). 
A final administration of Xeomin 25 U/animal was given 
10 weeks after the eighth injection. Conversely, Dysport 
was given twice weekly at 40 U/kg of animal for five 
administrations, with a lowered dose of 20 U/kg of   animal 
for the final administration, over a period of 13 weeks 
(cumulative dose 220 U/kg of animal; data on file, Merz 
Pharmaceuticals GmbH). Unlike the two conventional botu-
linum toxin type A drugs, Xeomin was not associated with 
the development of neutralizing antibodies in this animal 
model. Indeed, 15 rabbits developed neutralizing   antibodies 
after six injections of Dysport, while four rabbits had 
  neutralizing antibodies following nine injections of Botox 
(data on file, Merz Pharmaceuticals GmbH). Thus, Xeomin 
shows low immunogenicity even using doses four to five 
times higher than the equivalent clinically recommended 
highest doses for humans in therapeutic indications.52,53 
While this suggests that Xeomin presents a lower risk of 
generating antibodies, it remains to be confirmed whether 
these results are reflected in different species, such as 
humans, who may differ in their immune response. How-
ever, emerging data in humans do support these results. For 
example, in a recent study of up to 89 weeks in patients with 
upper limb spasticity who received one injection of Xeomin 
or placebo followed by up to five injections of Xeomin, no 
patient developed neutralizing antibodies throughout the 
study.54 In the clinical development program of Xeomin in 
the US, 12 of 1080 subjects developed antibodies against 
the neurotoxin but each of these patients was previously 
treated with a botulinum toxin product which contained 
complexing proteins and so may have already been primed 
by this treatment.55 For several reasons this outcome cannot 
be compared with other studies, eg, a different assay was 
used with a different sensitivity and specificity. Treatment 
with Xeomin may result in a reduced incidence of antibody-
induced therapy failure after long-term treatment compared 
with conventional botulinum toxin type A drugs but, in 
order to finally resolve this issue, the results of long-term 
comparative trials are required.
Conclusion
Complexing proteins do not contribute to the diffusion 
properties of botulinum toxin products. Furthermore, they 
are not required to stabilize the neurotoxin in the pharma-
ceutical formulation. Xeomin does not contain complexing 
proteins, yet retains safety and efficacy profiles equivalent to 
conventional botulinum toxin type A formulations. It would 
therefore appear that complexing proteins do not contribute 
to the therapeutic effect of botulinum toxin type A   treatment. 
Studies in animals suggest that complexing proteins may 
increase formation of antibodies against botulinum toxin Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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type A, which can lead to the termination of therapy in 
some patients, although further studies in human subjects 
are required to verify this finding.
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